{
  "trial_id": "NCT03674112",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, hormone receptor status, ECOG performance status, left ventricular ejection fraction (LVEF), prior neoadjuvant chemotherapy completion, surgical treatment completion, wound healing status, planned adjuvant radiotherapy, planned adjuvant hormone therapy, pregnancy status, history of active malignancy, history of serious cardiac illness, history of ventricular dysrhythmias, bone marrow function, renal function, liver function, presence of severe uncontrolled systemic disease, infection status, hypersensitivity to study drugs, chronic corticosteroid treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "Hormone receptor status",
          "hormone receptor status"
        ]
      ],
      "remaining_reference_features": [
        "Race",
        "Baseline weight",
        "Number of cycles of prior neoadjuvant",
        "Prior neoadjuvant chemotherapy regimen",
        "Pathological complete response to prior neoadjuvant treatment",
        "Histological subtype",
        "Histological grade",
        "Clinical stage at presentation"
      ],
      "remaining_candidate_features": [
        "gender",
        "left ventricular ejection fraction (LVEF)",
        "prior neoadjuvant chemotherapy completion",
        "surgical treatment completion",
        "wound healing status",
        "planned adjuvant radiotherapy",
        "planned adjuvant hormone therapy",
        "pregnancy status",
        "history of active malignancy",
        "history of serious cardiac illness",
        "history of ventricular dysrhythmias",
        "bone marrow function",
        "renal function",
        "liver function",
        "presence of severe uncontrolled systemic disease",
        "infection status",
        "hypersensitivity to study drugs",
        "chronic corticosteroid treatment"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Sex, Race, ECOG performance status, Hormone receptor status, HER2 status, Neoadjuvant chemotherapy regimen, Surgery type, Adjuvant radiotherapy status, Adjuvant hormone therapy status, Left ventricular ejection fraction (LVEF), Contraceptive use, Pregnancy status, History of active malignancy, Cardiac history, Renal function, Liver function, Bone marrow function, Infection status, Hypersensitivity history, Corticosteroid use",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race",
          "Race"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "Hormone receptor status",
          "Hormone receptor status"
        ],
        [
          "Prior neoadjuvant chemotherapy regimen",
          "Neoadjuvant chemotherapy regimen"
        ]
      ],
      "remaining_reference_features": [
        "Baseline weight",
        "Number of cycles of prior neoadjuvant",
        "Pathological complete response to prior neoadjuvant treatment",
        "Histological subtype",
        "Histological grade",
        "Clinical stage at presentation"
      ],
      "remaining_candidate_features": [
        "Sex",
        "HER2 status",
        "Surgery type",
        "Adjuvant radiotherapy status",
        "Adjuvant hormone therapy status",
        "Left ventricular ejection fraction (LVEF)",
        "Contraceptive use",
        "Pregnancy status",
        "History of active malignancy",
        "Cardiac history",
        "Renal function",
        "Liver function",
        "Bone marrow function",
        "Infection status",
        "Hypersensitivity history",
        "Corticosteroid use"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Sex, BMI, ECOG performance status, Hormone receptor status, HER2 status, Menopausal status, Prior chemotherapy, Prior radiotherapy, Prior hormone therapy, LVEF, Left ventricular ejection fraction (LVEF) by ECHO or MUGA scan.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "ECOG performance status",
          "ECOG performance status"
        ],
        [
          "Hormone receptor status",
          "Hormone receptor status"
        ],
        [
          "Prior neoadjuvant chemotherapy regimen",
          "Prior chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Race",
        "Baseline weight",
        "Number of cycles of prior neoadjuvant",
        "Pathological complete response to prior neoadjuvant treatment",
        "Histological subtype",
        "Histological grade",
        "Clinical stage at presentation"
      ],
      "remaining_candidate_features": [
        "Sex",
        "BMI",
        "HER2 status",
        "Menopausal status",
        "Prior radiotherapy",
        "Prior hormone therapy",
        "LVEF",
        "Left ventricular ejection fraction (LVEF) by ECHO or MUGA scan."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, hormone receptor status, HER2 status, type of breast cancer, prior neoadjuvant chemotherapy, prior surgery, adjuvant radiotherapy status, adjuvant hormone therapy status, left ventricular ejection fraction (LVEF).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Race",
          "race"
        ],
        [
          "ECOG performance status",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Hormone receptor status",
          "hormone receptor status"
        ],
        [
          "Prior neoadjuvant chemotherapy regimen",
          "prior neoadjuvant chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Baseline weight",
        "Number of cycles of prior neoadjuvant",
        "Pathological complete response to prior neoadjuvant treatment",
        "Histological subtype",
        "Histological grade",
        "Clinical stage at presentation"
      ],
      "remaining_candidate_features": [
        "sex",
        "ethnicity",
        "body mass index (BMI)",
        "HER2 status",
        "type of breast cancer",
        "prior surgery",
        "adjuvant radiotherapy status",
        "adjuvant hormone therapy status",
        "left ventricular ejection fraction (LVEF)"
      ]
    }
  }
}